Lacarnit 330 Tablet contains Levo-carnitine 330 mg, a naturally occurring amino acid derivative essential for energy metabolism. It plays a critical role in the transport of long-chain fatty acids into the mitochondria, facilitating their oxidation and subsequent ATP production. This medication is primarily indicated for the treatment of carnitine deficiency, which may result from genetic disorders, chronic renal failure, or certain metabolic conditions. Additionally, Lacarnit 330 is utilized as an adjunct therapy in patients with cardiovascular diseases, including ischemic heart disease and heart failure, to improve myocardial energy metabolism. It may also be prescribed to enhance exercise tolerance and reduce fatigue in various clinical scenarios. The tablet should be administered as directed by a healthcare professional, with dosage adjustments based on the severity of deficiency and patient response. Common adverse effects are generally mild and may include gastrointestinal disturbances such as nausea, vomiting, or abdominal cramps. Caution is advised in patients with hypersensitivity to Levo-carnitine or any tablet excipients. Lacarnit 330 Tablet should be stored in a cool, dry place, away from direct sunlight. Its use during pregnancy and lactation should be under medical supervision. Regular monitoring of clinical response and carnitine levels is recommended to optimize therapeutic outcomes.